We propose screening all patients without pathogenic variants in the COL1A1 and COL1A2 genes for the presence of pathogenic variants in the IFITM5 gene, even if they do not have the typical clinical symptoms of OI type V. This evidence concerns the gene COL1A2 and osteogenesis imperfecta type 5.